GeoVax Labs (NASDAQ:GOVX) Stock Rating Upgraded by Wall Street Zen

GeoVax Labs (NASDAQ:GOVX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

Several other research firms have also recently weighed in on GOVX. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Stock Performance

GOVX opened at $1.34 on Friday. GeoVax Labs has a 52-week low of $0.96 and a 52-week high of $24.88. The firm has a market capitalization of $4.65 million, a PE ratio of -0.07 and a beta of 3.62. The business’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $2.85.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Wednesday, April 15th. The company reported $1.85 EPS for the quarter. On average, research analysts forecast that GeoVax Labs will post -8.69 earnings per share for the current year.

Institutional Investors Weigh In On GeoVax Labs

A number of large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in GeoVax Labs during the 1st quarter valued at $27,000. Hudson Bay Capital Management LP acquired a new position in shares of GeoVax Labs in the third quarter valued at $47,000. HRT Financial LP acquired a new position in shares of GeoVax Labs in the fourth quarter valued at $31,000. Armistice Capital LLC bought a new position in shares of GeoVax Labs in the third quarter valued at about $253,000. Finally, Renaissance Technologies LLC bought a new position in shares of GeoVax Labs in the fourth quarter valued at about $104,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.